Stock Analysis
Zoetis Inc. (ZTS) Stock Analysis
Zoetis Inc. (ZTS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Zoetis Inc. (ZTS) currently has an AIQ Score of 68/100, indicating a neutral setup. Momentum is the strongest factor at 74/100. Value is the weakest current factor at 62/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ZTS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $79.62 |
| AIQ Score | 68/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $32.37B |
| P/E Ratio (TTM) | 12.7 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $1.65 |
| Revenue (quarter ended 2026-06-30) | $2.47B |
| Dividend Yield (TTM) | 2.71% |
| Beta | 0.73 |
| Volume | 3.04M |
| 52-week range | $68.77-$148.30 |
| RSI 14 | 83.56 |
| 50-Day SMA | $74.31 |
| 200-Day SMA | $95.16 |
| Analyst Price Target | $94.71 |
| Next Earnings | Nov 5, 2026 |
ZTSZoetis Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
Leader
Sector Leader
Latest quote
- Momentum74
- Value62
- Quality70
- Risk resilience63
- Sentiment—
ZTS Stock Analysis Summary
Zoetis Inc. (ZTS) currently has an AIQ Score of 68/100, indicating a neutral setup. Momentum is the strongest factor at 74/100. Value is the weakest current factor at 62/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ZTS has AIQ Score of 68/100 with Momentum base of 74/100 and fading Value at 62/100. Wait for component alignment before adding exposure.
Healthcare · -0.52% stock move · ZTS classified in Drug Manufacturers - Specialty & Generic.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ZTS Bullish or Bearish Right Now?
ZTS currently has a neutral overall setup. Momentum is the strongest factor at 74/100, while Value is weakest at 62/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 70/100.
- - Momentum is constructive at 74/100.
- - Risk Resilience is supportive at 63/100.
- - Price is +7.14% above its 50-day SMA.
- - Analyst target implies +18.95% upside from the latest quote.
- - Price is -16.33% below its 200-day SMA.
Current Consensus
ZTS's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 2 neutral, and 10 sell votes. ZTS's 14-day RSI is 83.56, which places the stock in an overbought momentum range. ZTS's beta is 0.73, indicating lower market sensitivity than the broad market.
What Changed in ZTS?
The largest recent change in ZTS is AIQ Score moving up by 0.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ZTS Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ZTS Decision Framework
Public evidence layers, setup checks, and risk context for Zoetis Inc..
Zoetis Inc. (ZTS) Stock Analysis
Zoetis Inc. has an AIQ Score of 68/100 in a Neutral regime. Momentum is strongest at 74/100. Beta is 0.74, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ZTS is in a Neutral AIQ regime with score 68/100. |
| Signal Conflict | The primary conflict is that momentum leads at 74/100 while value lags at 62/100. |
| Factor Evidence | Momentum 74/100 · Value 62/100 · Quality 70/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 74/100.
Momentum is 74/100 and RSI (14) is 83.6.
ZTS is in a Neutral regime at 68/100.
Risk factor is 63/100 with beta 0.74 and annual volatility 38.26%.
Current conflict: momentum leads at 74/100 while value lags at 62/100.
ZTS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ZTS Fundamentals
ZTS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ZTS Technical Analysis
ZTS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ZTS Stock Catalysts
Track ZTS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ZTS Dividend Analysis
ZTS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ZTS Financial Data
ZTS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ZTS Risk Analysis
ZTS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ZTS Stock News
ZTS stock news, market tone, recent headlines, and catalyst context.
ZTS vs Life Sciences / Tools / CRO Peers
Current peer cohort: ZTS · A · CDNA · CERT · CLVT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ZTS Current stock | 68/100 | 62/100 | 74/100 | 63/100 | -1.47 | 38.26% | Current |
| A Agilent Technologies | 60/100 | 37/100 | 77/100 | 64/100 | 0.71 | 32.48% | ZTS vs A |
| CDNA CareDx | 59/100 | 27/100 | 68/100 | 39/100 | 2.4 | 73.07% | ZTS vs CDNA |
| CERT Certara | 56/100 | 53/100 | 69/100 | 49/100 | -0.08 | 59.65% | ZTS vs CERT |
| CLVT Clarivate | 54/100 | 75/100 | 53/100 | 31/100 | -0.64 | 76.42% | ZTS vs CLVT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ZTS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ZTS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ZTS Stock FAQ
What is ZTS stock price today?
Zoetis Inc.'s current stock price is $79.62. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ZTS bullish or bearish right now?
ZTS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ZTS's market cap?
ZTS's market cap is $32.37B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ZTS's current P/E ratio?
ZTS's current P/E ratio is 12.7 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ZTS's RSI?
ZTS's 14-day RSI is 83.56 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ZTS above its 50-day and 200-day moving averages?
ZTS is 7.14% from its 50-day SMA and -16.33% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ZTS's next earnings date?
ZTS's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ZTS pay a dividend?
ZTS's dividend yield is 2.71% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.